Keywords: Genfit, GFT505, Insulin sensitivity

Genfit’s GFT505 improves insulin sensitivity

Article | 05 February 2012

Print This

French biotech firm Genfit (Alternext: ALGFT) says that its leading drug candidate GFT505 in a Phase II clinical study dubbed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in